U.S. markets closed
  • S&P 500

    3,638.35
    +8.70 (+0.24%)
     
  • Dow 30

    29,910.37
    +37.90 (+0.13%)
     
  • Nasdaq

    12,205.85
    +111.44 (+0.92%)
     
  • Russell 2000

    1,855.27
    +10.25 (+0.56%)
     
  • Crude Oil

    45.53
    -0.18 (-0.39%)
     
  • Gold

    1,788.10
    -23.10 (-1.28%)
     
  • Silver

    22.64
    -0.81 (-3.44%)
     
  • EUR/USD

    1.1970
    +0.0057 (+0.48%)
     
  • 10-Yr Bond

    0.8420
    -0.0360 (-4.10%)
     
  • GBP/USD

    1.3314
    -0.0042 (-0.32%)
     
  • USD/JPY

    104.0850
    -0.1650 (-0.16%)
     
  • BTC-USD

    18,112.65
    +344.59 (+1.94%)
     
  • CMC Crypto 200

    333.27
    -4.23 (-1.25%)
     
  • FTSE 100

    6,367.58
    +4.65 (+0.07%)
     
  • Nikkei 225

    26,644.71
    +107.40 (+0.40%)
     

Fulgent Genetics Inc (FLGT) Files 10-K for the Fiscal Year Ended on December 31, 2018

GuruFocus.com

- By insider

Fulgent Genetics Inc (FLGT) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Fulgent Genetics Inc is a technology company offering genetic testing to provide physicians with clinically actionable diagnostic information used to improve the overall quality of patient care. Fulgent Genetics Inc has a market cap of $97.570 million; its shares were traded at around $5.40 with and P/S ratio of 4.85.


For the last quarter Fulgent Genetics Inc reported a revenue of $5.68 million, compared with the revenue of $4.28 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $21.4 million, an increase of 14% from last year.

The reported loss per diluted share was 25 cents for the year, compared with the loss per share of $0.59 in the previous year. The Fulgent Genetics Inc had an operating margin of -23.68%, compared with the operating margin of -18.59% a year before. The 10-year historical median operating margin of Fulgent Genetics Inc is -35.47%. The profitability rank of the company is 3 (out of 10).

At the end of the fiscal year, Fulgent Genetics Inc has the cash and cash equivalents of $6.74 million, compared with $6.49 million in the previous year. The company had no long term debt. Fulgent Genetics Inc has a financial strength rank of 9 (out of 10).

At the current stock price of $5.40, Fulgent Genetics Inc is traded at 14.9% premium to its historical median P/S valuation band of $4.70. The P/S ratio of the stock is 4.85, while the historical median P/S ratio is 4.22. The stock gained 42.08% during the past 12 months.

CEO Recent Trades:

  • President and CEO, 10% Owner Ming Hsieh bought 8,739 shares of FLGT stock on 03/05/2019 at the average price of $4.95. The price of the stock has increased by 9.09% since.

CFO Recent Trades:

  • CFO and Treasurer Paul Kim sold 1,165 shares of FLGT stock on 03/05/2019 at the average price of $4.67. The price of the stock has increased by 15.63% since.

For the complete 20-year historical financial data of FLGT, click here.

This article first appeared on GuruFocus.